Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Capture of a Disabled Proteasome Identifies Erg25 as a Substrate for Endoplasmic Reticulum Associated Degradation

ABSTRACT: Proteasome, proteasome partners and ubiquitin-proteasome system (UPS) substrates were affinity purified from a yeast strain with an GFP-tagged proteasome subunit to which a proteasome inhibitor could be applied. Parallel experiments utilized inhibitor insensitive strains or strains lacking the tagged subunit. After affinity isolation, enriched proteins were resolved in SDS-PAGE, in-gel digested, and analyzed by high resolution liquid chromatography-tandem MS.

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Saccharomyces Cerevisiae By4741 (ncbitaxon:1247190)

SUBMITTER: Jeffrey L. Brodsky

PROVIDER: MSV000085914 | MassIVE | Wed Aug 05 07:21:00 BST 2020

SECONDARY ACCESSION(S): PXD020736

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

Protein abundance changes and ubiquitylation targets identified upon inhibition of the proteasome with Syringolin A

Project description:The numerous roles of the ubiquitin proteasome system (UPS) in cellular control have triggered interest in the identification of these ubiquitylation targets and their sites of ubiquitylation. For the identification of ubiquitylated proteins we employed affinity enrichment using an ubiquitin binding domains (UBAs). A change in the experimental set-up allowed for the identification of proteins that so far have been refractory to identification. We also investigated the changes in protein abundance upon interfering with the UPS by inhibition of the proteasome with the specific inhibitor Syringolin A and using a mutant overexpressing ubiquitin that cannot form K48-linked polyubiquitin chains.

2014-04-15 | PXD000566 | Pride

Protein abundance changes and ubiquitylation targets identified upon inhibition of the proteasome with Syringolin A

2014-04-15 | PXD000521 | Pride

Protein abundance changes and ubiquitylation targets identified upon inhibition of the proteasome with Syringolin A

2014-04-15 | PXD000567 | Pride

Protein abundance changes and ubiquitylation targets identified upon inhibition of the proteasome with Syringolin A

2014-05-19 | PXD000568 | Pride

Protein abundance changes and ubiquitylation targets identified upon inhibition of the proteasome with Syringolin A

2014-04-15 | PXD000565 | Pride

A Homeostatic Shift Facilitates Endoplasmic Reticulum Proteostasis through Transcriptional Integration of Proteostatic Stress Response Pathways [expression]

Project description:Eukaryotic cells maintain protein homeostasis through the activity of multiple basal and inducible systems, which function in concert to allow cells to adapt to a wide range of environmental conditions. Although the transcriptional programs regulating individual pathways have been studied in detail, it is not known how the different pathways are transcriptionally integrated such that a deficiency in one pathway can be compensated by a change in an auxiliary response. One such pathway that plays an essential role in many proteostasis responses is the ubiquitin-proteasome system, which functions to degrade damaged, unfolded, or short half-life proteins. Transcriptional regulation of the proteasome is mediated by the transcription factor Nrf1. Using a conditional knockout mouse model, we found that Nrf1 regulates protein homeostasis in the endoplasmic reticulum (ER) through transcriptional regulation of the ER stress sensor ATF6. In Nrf1 conditional-knockout mice, a reduction in proteasome activity is accompanied by an ATF6-dependent downregulation of the endoplasmic reticulum-associated degradation machinery, which reduces the substrate burden on the proteasome. This indicates that Nrf1 regulates a homeostatic shift through which proteostasis in the endoplasmic reticulum and cytoplasm are coregulated based on a cell's ability to degrade proteins.

2016-12-21 | GSE89310 | GEO

Endoplasmic reticulum di-glycine modified proteome under p97/VCP inhibition

Project description:Endoplasmic reticulum (ER)-associated degradation (ERAD) mediates the proteasomal clearance of proteins from the early secretory pathway. In this process, ubiquitinated substrates are extracted from membrane-embedded dislocation complexes by the AAA ATPase VCP and targeted to the cytosolic 26S proteasome. In addition to its well-established role in the degradation of misfolded proteins, ERAD also regulates the abundance of key proteins such as enzymes involved in cholesterol synthesis. However, due to the lack of generalizable methods, our understanding of the scope of proteins regulated targeted by ERAD remains limited. To overcome this obstacle, we developed a VCP-inhibitor substrate trapping approach (VISTA) to identify endogenous ERAD substrates. VISTA exploits the small-molecule VCP inhibitor CB5083 to trap ERAD substrates in a membrane-associated, ubiquitinated form.

2018-03-12 | PXD008842 | Pride

A Homeostatic Shift Facilitates Endoplasmic Reticulum Proteostasis through Transcriptional Integration of Proteostatic Stress Response Pathways [ChIP-seq]

2016-12-21 | GSE89344 | GEO

PIASy overexpression effects on gene expression in mouse 2-cell embryos

Project description:During the maternal-to-zygotic transition (MZT), maternal mRNAs and proteins are degraded, and zygotic genes are activated. We have previously shown that the ubiquitin-proteasome system (UPS) after fertilization plays a role in onset of zygotic transcription. However, the maternal proteins, which are degraded by UPS and can contribute to the zygotic transcription, have not been identified. Here, we identified PIASy (Protein inhibitor of activated STAT y), which is an E3 SUMO ligase, as the maternal proteins that were degraded via UPS after fertilization and by examining the overexpression of PIASy. We observed developmental arrest at the mouse 2-cell stage. Therefore, we examined the effect of PIASy overexpression on zygotic gene expression by using the RNA-sequencing analysis.

2019-10-23 | GSE126056 | GEO

Gene expression profile of multiple myeloma cell lines treated with CB-5083

Project description:The goal was to determine the gene expression differences between CB-5083 and Bortezomib treated multiple myeloma cell lines Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system (UPS) and CB-5083, a first in class inhibitor of p97, has demonstrated broad antitumor activity in a range of both hematological and solid tumor models. Here, we show that CB-5083 has robust activity against multiple myeloma (MM) cell lines and a number of in vivo MM models. Treatment with CB-5083 is associated with accumulation of ubiquitinated proteins, induction of the unfolded protein response (UPR) and apoptosis. CB-5083 decreases viability in MM cell lines and patient derived MM cells, including those with background proteasome inhibitor (PI) resistance. CB-5083 has a unique mechanism of action that combines well with PIs which is likely owing to the p97-dependent retro-translocation of the transcription factor, Nrf1, which transcribes proteasome subunit genes following exposure to a PI. In vivo studies using clinically relevant MM models demonstrate that single-agent CB-5083 inhibits tumor growth and combines well with MM standard of care agents. Our preclinical data demonstrate the efficacy of CB-5083 in several MM disease models and provide the rationale for clinical evaluation as monotherapy and in combination in MM.

2017-10-26 | GSE101923 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data